<DOC>
	<DOC>NCT00384631</DOC>
	<brief_summary>Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described. We aim to evaluate the effect of three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures include intraocular pressure and extent of iris neovascularization. Both study arms will receive conventional treatment for NVG.</brief_summary>
	<brief_title>Intravitreal Bevacizumab for Neovascular Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Neovascular</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Clinical diagnosis of NVG Vision less than 20/200 age 1080 years Uncontrolled Blood Pressure History of thromboembolism Congestive Heart Failure Renal Failure Pregnancy or Lactation Active ocular or periocular infection No light perception</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Neovascular</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Intravitreal</keyword>
	<keyword>IOP</keyword>
</DOC>